DNA methylation profiling can classify HIV-associated lymphomas
DNA methylation profiling can classify HIV-associated lymphomas
复制标题
DOI：
10.1097/qad.0000000000000120
复制
发表时间：
2014-02-20
期刊：
影响因子：
3.8
通讯作者：
Hagiwara, Shotaro
中科院分区：
文献类型：
--
作者：
Matsunaga, Akihiro;Hishima, Tsunekazu;Hagiwara, Shotaro
背景：HIV阳性患者非霍奇金淋巴瘤的发病率增加60倍至200倍，包括伯基特淋巴瘤、弥漫性大B细胞淋巴瘤和原发性中枢神经系统淋巴瘤。 HIV相关淋巴瘤通常具有结外受累、对标准化疗的反应降低和高复发率等特征，这些特征表明预后不良。一般病理特征并不能明确区分 HIV 相关淋巴瘤和非 HIV 淋巴瘤。方法：为了研究 HIV 相关淋巴瘤的特征，我们使用 Illumina GoldenGate Mmethylation Cancer Panel I 和 Illumina Infinium HumanMmethylation450 BeadChip 微阵列对 HIV 和非 HIV 淋巴瘤进行全基因组 DNA 甲基化分析。使用无监督的层次聚类分析对 HIV 相关淋巴瘤和非 HIV 淋巴瘤的 DNA 甲基化谱进行了表征。结果：启动子区域的分析揭示了 HIV 相关淋巴瘤中独特的 DNA 甲基化谱，表明与非 HIV 淋巴瘤相比存在谱差异，这意味着 HIV 相关淋巴瘤中涉及 DNA 甲基化的特定基因调控。基于 HumanMmethylation450 BeadChip 数据，使用 Wilcoxon 的秩和检验选择了 2541 个靶位点，这些位点在 HIV 相关淋巴瘤和非 HIV 相关淋巴瘤之间的比较中存在显着差异（P
Background:HIV-positive patients have a 60-fold to 200-fold increased incidence of non-Hodgkin lymphomas, including Burkitt lymphoma, diffuse large B-cell lymphoma, and primary central nervous system lymphoma. HIV-associated lymphomas frequently have features such as extranodal involvement, decreased responses to standard chemotherapy, and high relapse rates, which indicate a poor prognosis. General pathological features do not clearly differentiate HIV-associated lymphomas from non-HIV lymphomas.Methods:To investigate the features of HIV-associated lymphomas, we performed genome-wide DNA methylation profiling of HIV and non-HIV lymphomas using Illumina GoldenGate Methylation Cancer Panel I and Illumina Infinium HumanMethylation450 BeadChip microarrays. DNA methylation profiles in HIV-associated and non-HIV lymphomas were characterized using unsupervised hierarchical clustering analyses.Results:The analyses of promoter regions revealed unique DNA methylation profiles in HIV-associated lymphomas, suggesting profile differences compared with non-HIV lymphomas, which implies specific gene regulation in HIV-associated lymphoma involving DNA methylation. Based on HumanMethylation450 BeadChip data, 2541 target sites were selected as differing significantly in comparisons between HIV-associated and non-HIV-associated lymphomas using Wilcoxon's rank-sum test (P